

# Anti- Human HLA-B27 (HLA-ABC-m3)

			
FITC	HLAB27F-I00T	100 test	RUO

## 1. PRODUCT DESCRIPTION

**Clone:** HLA-ABC-m3  
**Isotype:** Mouse / IgG2a  
**Tested application:** flow cytometry  
**Immunogen:** Immune complex precipitated from HLA-B27 positive cell line (Bordin).  
**Species reactivity:** Human  
**Storage instruction:** store in the dark at 2-8 °C  
**Storage buffer:** aqueous buffered solution containing protein stabilizer and 0.09% sodium azide (NaN3).  
**Recommended usage:** Immunostep's HLA-B27 FITC is a monoclonal antibody intended for the identification and enumeration of cells expressing the HLA-B27 surface antigen, a class I molecule encoded by the B locus of the human Major Histocompatibility Complex (MHC). This antigen plays a key role in presenting microbial peptides to T cells. This reagent is effective for direct immunofluorescence staining of human tissue for flow cytometric analysis using I test for I06 cells.  
**Presentation:** liquid  
**Source:** Supernatant proceeding from an in vitro cell culture of a cell hybridoma.  
**Purification:** Affinity chromatography.

## 2. ANTIGEN DETAILS

**Large description:** The monoclonal antibody Anti-HLA-B27 is directed against the HLA-B27 antigen, a class I surface molecule encoded by the B locus of the human Major Histocompatibility Complex (MHC). This antigen plays a key role in the presentation of microbial peptides to T cells, contributing to immune recognition and response I.

HLA-B27 is expressed in approximately 7% of the Caucasian population, while a related antigen, HLA-B7, is found in about 22%2. The detection of HLA-B27 is clinically significant due to its strong association with inflammatory diseases, particularly ankylosing spondylitis. Over 90% of individuals diagnosed with ankylosing spondylitis express the HLA-B27 antigen, compared to only 7% of asymptomatic individuals3.

This monoclonal antibody enables the identification of HLA-B27 specificity within the class I HLA allotype, supporting the diagnosis and monitoring of spondyloarthropathies. Flow cytometry using CYT-HLAIB27F provides a rapid and reliable method for assessing HLA-B27 expression in clinical samples 3.

Furthermore, structural and functional studies have shown that HLA-B27 may contribute to disease pathogenesis through mechanisms involving misfolding, aberrant immune responses, and interactions with innate immune receptors.

Other Names: HLA class I histocompatibility antigen, B alpha chain, HLA-B, HLAB  
Gene ID: 3106  
Molecular weight: 45 kDa

For research use only, not for diagnostic procedures.  
Please, refer to [www.immunostep.com](http://www.immunostep.com) technical support for more information.

## 3. WARRANTY








Warranted only to conform to the quantity and contents stated on the label or in the product labelling at the time of delivery to the customer. Immunostep disclaims hereby other warranties.

Immunostep's sole liability is limited to either thereplacement of the products or refund of the purchase price.

## 4. REFERENCES

- Colombani J. HLA - Fonctions immunitaires et applications médicales. John Libbey Eurotext., pp 285 (1993).
- Lee TD. Distribution of HLA antigens in North American populations. In: The HLA System, A New Approach. John Lee, Ed. (1990).
- Fizet D. Identification de l'antigène HLA B27 par cytométrie de flux. Ann. Biol. Clin. 47: 408-411 (1989).
- Bodmer J. World distribution of HLA alleles and implications for disease. Ciba Foundation Symposium. 197: 233-258 (1996).
- Lopez-Larrea C, Gonzalez-Roces S, Alvarez V. HLA-B27 structure, function and disease association. Curr. Opin. Rheumatol., 8: 296-308 (1996).
- Bowness P. HLA B27 in health and disease: a double-edged sword? Rheumatology 41: 857-868 (2002).

## 5. EXPLANATION OF SYMBOLS

	Form
	Catalog reference
	Contains sufficient for <n> test
	Quantity per test
	Regulatory Status
	Research Use Only
	Manufacturer

## 6. MANUFACTURED BY:



**Address:** Avda. Universidad de Coimbra, s/n  
Cancer Research Center (C.I.C)  
Campus de Unamuno  
37007 Salamanca (Spain)  
**Telf./fax:** (+34) 923 294 827  
**E-mail:** [info@immunostep.com](mailto:info@immunostep.com)  
[www.immunostep.com](http://www.immunostep.com)